More than 26 million people worldwide have been prescribed XARELTO®1
Reducing Stroke Risk in Nonvalvular AF
Proven efficacy and safety outcomes achieved in patients with prior stroke or multiple comorbidities
ROCKET AF Diabetes Subgroup Analysis
Diabetes and its treatment can complicate stroke risk reduction in nonvalvular AF. Learn how XARELTO® showed consistent results in NVAF patients with diabetes
Explore real-world safety and efficacy outcomes
AF = atrial fibrillation; NVAF = nonvalvular atrial fibrillation.